Dopamine-induced death of PC12 cells is prevented by a substituted tetrahydronaphthalene

Neuropharmacology

Volumn 46, Issue 7, 2004, Pages 984-993

  Song, Jin H ^a   Slot, Andrew J ^a   Ryan, Roby W J ^a   Ross, Gregory M ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

BHT, butylated hydroxy toluene; Caspase; Catecholamine; CATNAP, catecholamine arylated protein; DA, dopamine; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

6 HYDROXY [N (N' 2',4' DINITROPHENYL)AMINOPROPYL] 2 AMINO 1,2,3,4 TETRAHYDRONAPHTHALENE; CASPASE 3; DICHLORODIHYDROFLUORESCEIN; DOPAMINE; FLUORESCEIN DERIVATIVE; HYDROGEN PEROXIDE; LIPID PEROXIDE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; ARYLATION; CELL DEATH; CELL PROTECTION; CELL STRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HYPOTHESIS; INTRACELLULAR SPACE; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REDUCTION;

ANIMALS; APOPTOSIS; CELL DEATH; CELL SURVIVAL; DOPAMINE; PC12 CELLS; RATS; TETRAHYDRONAPHTHALENES;

EID: 1842815160     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2004.01.001     Document Type: Article

References (48)

1. Berman S.B., Hastings T.G. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. Journal of Neurochemistry. 69:1997;1185-1195.
2. Berman S.B., Hastings T.G. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. Journal of Neurochemistry. 73:1999;1127-1137.
3. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods in Enzymology. 52:1978;302-310.
4. Cheng F.C., Kuo J.S., Chia L.G., Dryhurst G. Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. Journal of Neural Transmission. 103:1996;433-446.
5. Choi H.Y., Song J.H., Park D.K., Ross G.M. The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics. Neuroscience Letters. 296:2000;81-84.
6. Coyle J.T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
7. Crow J.P. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for intracellular measurements of reactive nitrogen and oxygen species. Nitric Oxide: Biology and Chemistry. 1:1997;145-157.
8. Drukarch B., Jongenelen C.A., Schepens E., Langeveld C.H., Stoof J.C. Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease. Journal of Neuroscience. 16:1996;6038-6045.
9. Dryhurst G. Are dopamine, norepinephrine, and serotonin precursors of biologically reactive intermediates involved in the pathogenesis of neurodegenerative brain disorders? Advances in Experimental and Medical Biology. 500:2001;373-396.
10. Gabriele J., Rajaram M., Zhang B., Sharma S., Mishra R.K. Modulation of a 40-kDa catecholamine-regulated protein following D-amphetamine treatment in discrete brain regions. European Journal of Pharmacology. 453:2002;13-19.
11. 2 and 6-hydroxydopamine. Movement Disorders. 13:1998;661-667.
12. Gasser T. Genetics of Parkinson's disease. Annals of Neurology. 44:1998;S53-S57.
13. Hastings T.G., Zigmond M.J. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H]dopamine: impact of ascorbic acid and glutathione. Journal of Neurochemistry. 63:1994;1126-1132.
14. Hastings T.G., Zigmond M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. Journal of Neural Transmission. 49:1997;S103-S110.
15. Jones D.C., Gunasekar P.G., Borowitz J.L., Isom G.E. Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells. Journal of Neurochemistry. 74:2000;2296-2304.
16. Lautraite S., Bigot-Lasserre D., Bars R., Carmichael N. Optimization of cell-based assays for medium throughput screening of oxidative stress. Toxicology in Vitro. 17:2003;207-220.
17. Lemasters J.J., Nieminen A.L., Qian T., Trost L.C., Elmore S.P., Nishimura Y., Crowe R.A., Cascio W.E., Bradham C.A., Brenner D.A., Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochimica Biophysica Acta. 1366:1998;177-196.
18. Li H., Dryhurst G. Oxidative metabolites of 5-S-cysteinyldopamine inhibit the pyruvate dehydrogenase complex. Journal of Neural Transmission. 108:2001;1363-1374.
19. Li H., Shen X.M., Dryhurst G. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: potential relevance to the pathogenesis of Parkinson's disease. Journal of Neurochemistry. 71:1998;2049-2062.
20. McLaughlin B.A., Nelson D., Erecinska M., Chesselet M.F. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by a mitochondrial inhibitor. Journal of Neurochemistry. 70:1998;2406-2415.
21. Melamed E., Offen D., Shirvan A., Djaldetti R., Barzilai A., Ziv I. Levodopa toxicity and apoptosis. Annals of Neurology. 44:1998;S149-S154.
22. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H., Kondo T. Mitochondrial dysfunction in Parkinson's disease. Annals of Neurology. 44:1998;S99-S109.
23. Modi P.I., Kashyap A., Nair V.D., Ross G.M., Fu M., Savelli J.E., Marcotte E.R., Barlas C., Mishra R.K. Modulation of brain catecholamine absorbing proteins by dopaminergic agents. European Journal of Pharmacology. 299:1996;213-220.
24. Morrison B.M., Hof P.R., Morrison J.H. Determinants of neuronal vulnerability in neurodegenerative diseases. Annals of Neurology. 44:1998;S32-S44.
25. 2 oxidation of dopamine. Journal of Medicinal Chemistry. 38:1995;917-922.
26. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
27. Noh J.S., Kim E.Y., Kang J.S., Kim H.R., Oh Y.J., Gwag B.J. Neurotoxic and neuroprotective actions of catecholamines in cortical neurons. Experimental Neurology. 159:1999;217-224.
28. Ohgoh M., Kimura M., Ogura H., Katayama K., Nishizawa Y. Apoptotic cell death of cultured cerebral cortical neurons induced by withdrawal of astroglial trophic support. Experimental Neurology. 149:1998;51-63.
29. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annual Review of Neuroscience. 22:1999;123-144.
30. Panet H., Barzilai A., Daily D., Melamed E., Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. Journal of Neurochemistry. 77:2001;391-398.
31. Rabinovic A.D., Hastings T.G. Role of endogenous glutathione in the oxidation of dopamine. Journal of Neurochemistry. 71:1998;2071-2078.
32. Ross G.M., McCarry B.E., Thakur S., Mishra R.K. Identification of novel catecholamine absorbing proteins in the central nervous system. Journal of Molecular Neuroscience. 4:1993;141-148.
33. Ross G.M., McCarry B.E., Mishra R.K. Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene. Journal of Neurochemistry. 65:1995;2783-2789.
34. Ross G.M., Shamovsky I.L., Lawrance G., Solc M., Dostaler S.M., Jimmo S.L., Weaver D.F., Riopelle R.J. Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins. Nature Medicine. 3:1997;872-878.
35. Sam E.E., Verbeke N. Free radical scavenging properties of apomorphine enantiomers and dopamine: possible implication in their mechanism of action in Parkinsonism. Journal of Neural Transmission. 10:1995;115-127.
36. Schapira A.H., Gu M., Taanman J.W., Tabrizi S.J., Seaton T., Cleeter M., Cooper J.M. Mitochondria in the etiology and pathogenesis of Parkinson's disease. Annals of Neurology. 44:1998;S89-S98.
37. Sharan N., Chong V.Z., Nair V.D., Mishra R.K., Hayes R.J., Gardner E.L. Cocaine treatment increases expression of a 40 kDa catecholamine-regulated protein in discrete brain regions. Synapse. 47:2002;33-44.
38. Si F., Ross G.M., Shin S.H. Glutathione protects PC12 cells from ascorbate- and dopamine-induced apoptosis. Experimental Brain Research. 123:1998;263-268.
39. Sidell K.R., Amamath V., Montine T.J. Dopamine thioethers in neurodegeneration. Current Topics in Medicinal Chemistry. 1:2001;519-527.
40. Sofic E., Denisova N., Youdim K., Vatrenjak-Velagic V., De Filippo C., Mehmedagic A., Causevic A., Cao G., Joshep J.A., Prior R.L. Antioxidant and pro-oxidant capacity of catecholamines and related compounds. Effects of hydrogen peroxide on glutathione and sphingomyelinase activity in pheochromocytoma PC12 cells: potential relevance to age-related diseases. Journal of Neural Transmission. 108:2001;541-557.
41. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. Journal of Neurochemistry. 71:1998;2112-2122.
42. Spencer J.P., Whiteman M., Jenner P., Halliwell B. 5-S-Cysteinyl- conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. Journal of Neurochemistry. 81:2002;122-129.
43. Steranka L.R., Rhind A.W. Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. European Journal of Pharmacology. 133:1987;191-197.
44. Tatton N.A., Maclean-Fraser A., Tatton W.G., Perl D.P., Olanow C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Annals of Neurology. 44:1998;S142-S148.
45. Velez-Pardo C., Jimenez Del Rio M., Ebinger G., Vauquelin G. Redox cycling activity of monoamine-serotonin binding protein conjugates. Biochemical Pharmacology. 51:1996;1521-1525.
46. Wang H., Joseph J.A. Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radicals in Biology and Medicine. 27:1999;612-616.
47. Whitehead R.E., Ferrer J.V., Javitch J.A., Justice J.B. Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. Journal of Neurochemistry. 76:2001;1242-1251.
48. Zilkha-Falb R., Ziv I., Nardi N., Offen D., Melamed E., Barzilai A. Monoamine-induced apoptotic neuronal cell death. Cell and Molecular Neurobiology. 17:1997;101-118.